查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047062

抗體片段市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、應用、特異性、地區和競爭格局分類，2021-2031年

Antibody Fragments Market - Global Industry Size, Share, Trends, Opportunity, and Forecast Segmented By Product Type, By Application, By Specificity, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球抗體片段市場預計將從 2025 年的 96.1 億美元成長到 2031 年的 132.2 億美元，複合年成長率為 5.46%。

抗體片段，包括Fab、scFv和單域抗體等修飾蛋白片段，具有組織滲透性增強、免疫抗原性降低等優勢，同時維持了全長免疫球蛋白精準的抗原結合能力。市場成長的主要驅動力是：對能夠針對深層腫瘤組織的癌症療法的需求不斷成長，以及微生物發酵帶來的經濟效益——與哺乳動物細胞培養相比，微生物發酵顯著降低了生產成本。近期監管方面的進展也印證了這個充滿活力的市場環境。根據抗體協會（The Antibody Society）報告，美國食品藥物管理局（FDA）在2024年核准了創紀錄的15種新型抗體療法。這凸顯了生物製藥領域加速創新，而這正是推動抗體片段技術發展的關鍵。

市場概覽
預測期 2027-2031
市場規模：2025年 96.1億美元
市場規模：2031年 132.2億美元
複合年成長率：2026-2031年 5.46%
成長最快的細分市場 癌症
最大的市場 北美洲

儘管抗體片段市場前景廣闊，但全球抗體片段市場仍面臨著許多挑戰，包括這些小分子固有的不穩定性以及快速的腎臟清除。雖然較小的分子尺寸有利於組織滲透，但其在血液中較短的半衰期通常需要頻繁給藥或進行諸如聚乙二醇化（PEGylation）等高級化學修飾才能維持治療效果。這些製劑的挑戰使藥物研發流程複雜化，增加了技術風險，並成為基於片段治療方法的大規模商業性化應用的主要障礙。

市場促進因素

全球慢性病和癌症發生率的不斷上升是全球抗體片段市場的主要驅動力，催生了對療效更佳、組織穿透性更強的治療藥物的需求。與有時難以穿透緻密固態腫瘤的全長抗體相比，Fab 和 scFv 等抗體片段由於分子尺寸較小，能夠更深入地滲透到複雜的組織微環境中。癌症疾病負擔的日益惡化進一步凸顯了這個關鍵的臨床需求。根據美國癌症協會於 2025 年 1 月發布的《2025 年癌症事實與數據》報告，預計到 2025 年，光是美國就將新增超過 200 萬例癌症病例。因此，市場正在擴張並積極接納這些基於抗體片段的治療方法。它們正擴大應用於標靶放射免疫療法和診斷影像，以滿足那些無法有效接受傳統生物製藥治療的患者的需求。

同時，生物製藥研發資金正顯著成長，加速了片段技術從工程概念轉換成商業性可行性的。領先的製藥公司正大幅增加資本投入，以克服穩定性問題，並開發利用片段模組化特性的先進雙特異性抗體結構。例如，根據賽諾菲於2025年1月發布的“2024年第四季及全年業績報告”，該公司2024年的研發支出成長了14.6%，達到74億歐元，這表明整個行業都致力於創新。這筆資金的湧入正在建立一個強大的開發平臺，預計將按計畫達到監管里程碑。歐洲藥品管理局（EMA）在2025年報告稱，其在前一年建議批准114種藥物核准，這表明監管環境有利於包括抗體衍生物在內的先進治療藥物的商業化。

市場挑戰

抗體片段的快速腎臟清除和固有的不穩定性是限制全球市場成長的主要障礙。由於這些小分子化合物的腎清除率通常低於腎濾過閾值，其循環半衰期顯著縮短，需要頻繁給藥才能維持療效。這給患者帶來負擔，並迫使研發人員進行複雜的化學修飾以延長作用時間。這些額外的製作流程帶來了顯著的技術風險和生產成本，削弱了片段生產通常具有的經濟優勢，並使商業化之路更加複雜。

這些研發障礙直接導致高失敗率，限制了最終上市的候選藥物數量。平衡最佳藥物動力學和標靶親和性的難度是實現規模化生產的一大障礙。根據抗體學會預測，到2024年，抗體療法獲得臨床核准的成功率預計在14%至32%之間。這項數據凸顯了研發者面臨的巨大風險，因為穩定性相關的技術挑戰仍然限制著基於片段的創新成果成功轉化為核准藥物。

市場趨勢

雙特異性和多特異性片段結構的日益普及正在從根本上改變市場格局，其構建體能夠同時捕獲多個靶點，從而實現對免疫細胞的精準募集。與傳統的單株抗體不同，這些形式，例如雙特異性T細胞銜接器（BiTE），利用連接的單鏈可變區（scFv）在細胞毒性T細胞和腫瘤相關抗原之間形成物理突觸，從而增強對複雜惡性腫瘤的療效。這種向先進多標靶療法的轉變正在推動顯著的商業性成長。根據安進公司於2025年2月發布的“2024年第四季及全年業績”，雙特異性T細胞銜接器Blincyto的全年銷售額成長了41%，這主要得益於其在急性淋巴性白血病治療方法中的應用日益廣泛。

同時，隨著源自駱駝科動物的單域抗體研發的蓬勃發展，VHH結構域（奈米抗體）的應用正被優先考慮，以克服傳統片段工程固有的穩定性限制。這些源自駱駝科動物的偶聯分子由於其高溶解性和模組化特性，正擴大被整合到治療平台中，使其成為嵌合體抗原受體（CAR）療法的理想組成部分。 CAR療法需要強大的抗原辨識能力，以防止抗原辨識能力下降。近期行業趨勢表明，這些特殊構建體的快速商業性強勁。根據強生公司於2025年1月發布的“2024年第四季及全年財務業績”，其CAR-T療法Carvykti（一種包含源自駱駝科動物的偶聯結構域的療法）的全球銷售額達到9.63億美元，同比成長92.7%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球抗體片段市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按產品類型（FAB、scFv、sdAb、其他）
    • 透過申請（癌症、免疫力缺乏、其他）
    • 依特異性（單株抗體、多株抗體）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美抗體片段市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲抗體片段市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區抗體片段市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲抗體片段市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美抗體片段市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球抗體片段市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Genentech Inc.
  • AbbVie Inc.
  • Albynx, a Sanofi Company
  • Johnson and Johnson
  • Pfizer Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19516

The Global Antibody Fragments Market is projected to expand from USD 9.61 Billion in 2025 to USD 13.22 Billion by 2031, reflecting a compound annual growth rate of 5.46%. Antibody fragments, including engineered protein segments such as Fabs, scFvs, and single-domain antibodies, preserve the precise antigen-binding capabilities of full-length immunoglobulins while providing advantages like enhanced tissue penetration and lower immunogenicity. Market growth is primarily fueled by the rising need for targeted oncology treatments capable of accessing deep tumor tissues, as well as the economic benefits of microbial manufacturing, which significantly reduces production costs relative to mammalian cell culture. This dynamic environment is evidenced by recent regulatory achievements; The Antibody Society reported that in 2024, the US Food and Drug Administration (FDA) approved a record-breaking 15 new antibody-based therapeutics, highlighting the accelerated innovation within the biologics sector that supports fragment advancement.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 9.61 Billion
Market Size 2031USD 13.22 Billion
CAGR 2026-20315.46%
Fastest Growing SegmentCancer
Largest MarketNorth America

Despite these favorable growth prospects, the Global Antibody Fragments Market confronts a major obstacle related to the inherent instability and rapid renal clearance associated with these smaller molecules. While their reduced molecular size facilitates tissue infiltration, it also leads to a brief circulatory half-life, often necessitating frequent administration or sophisticated chemical modifications, such as PEGylation, to sustain therapeutic levels. These formulation challenges add complexity to the drug development pipeline and elevate technical risks, serving as a considerable barrier to the widespread commercial scalability of fragment-based therapies.

Market Driver

The rising global incidence of chronic diseases and cancer acts as the main catalyst for the Global Antibody Fragments Market, creating a demand for therapeutics with improved efficacy and superior tissue accessibility. In contrast to full-length antibodies that may struggle to penetrate dense solid tumors, antibody fragments like Fabs and scFvs possess a smaller molecular footprint that enables deeper access into complex tissue microenvironments. This critical clinical need is emphasized by the growing burden of oncological conditions; according to the American Cancer Society's 'Cancer Facts & Figures 2025' report released in January 2025, over 2 million new cancer cases are projected to be diagnosed in the United States alone during 2025. Consequently, the market is expanding to incorporate these fragment-based modalities, which are increasingly applied in targeted radioimmunotherapy and diagnostic imaging to address the needs of patients who are not effectively treated by conventional biologics.

Concurrently, substantial increases in biologics research and development funding are accelerating the translation of fragment technologies from engineering concepts to commercial viability. Leading pharmaceutical companies are heavily increasing capital allocation to resolve stability issues and create advanced bispecific constructs that leverage the modularity of fragments. For instance, Sanofi's 'Fourth Quarter and Full Year 2024 Results' from January 2025 indicated that the company's research and development expenses rose by 14.6% to reach €7.4 billion in 2024, demonstrating a sector-wide dedication to innovation. This financial influx establishes a robust development pipeline that is successfully achieving regulatory milestones; the European Medicines Agency reported in 2025 that it recommended 114 medicines for marketing authorisation in the preceding year, illustrating a supportive regulatory landscape for the commercialization of advanced therapeutic classes, including antibody derivatives.

Market Challenge

The rapid renal clearance and inherent instability of antibody fragments represent a primary impediment to the growth of the global market. Because these smaller molecules frequently fall below the renal filtration threshold, they exhibit a significantly reduced circulatory half-life, necessitating frequent dosing to preserve therapeutic efficacy. This requirement places a burden on patients and forces developers to employ complex chemical modifications to prolong the duration of action. Such additional processing steps introduce significant technical risks and manufacturing costs, diminishing the economic advantages typically linked to fragment production and complicating the pathway to commercialization.

These developmental hurdles directly contribute to high attrition rates, restricting the number of candidates that successfully reach the market. The difficulty in balancing optimal pharmacokinetics with target affinity acts as a significant barrier to scalability. According to The Antibody Society, the clinical approval success rate for antibody therapeutics in 2024 was estimated to range between 14% and 32%. This statistic highlights the substantial risk profile facing developers, as technical challenges related to stability continue to limit the successful translation of fragment-based innovations into approved medicines.

Market Trends

The increasing adoption of bispecific and multispecific fragment architectures is fundamentally transforming the market by enabling precise immune cell recruitment through engineered constructs that engage multiple targets simultaneously. Unlike conventional monoclonal antibodies, these formats, such as Bispecific T-cell Engagers (BiTEs), use linked single-chain variable fragments to create a physical synapse between cytotoxic T-cells and tumor-associated antigens, thereby enhancing potency against complex malignancies. This shift toward sophisticated multi-targeting modalities is driving substantial commercial growth; according to Amgen's 'Fourth Quarter and Full Year 2024 Financial Results' published in February 2025, sales of the bispecific T-cell engager Blincyto rose by 41% for the full year, driven by expanded adoption in acute lymphoblastic leukemia treatment regimens.

At the same time, the surge in camelid-derived single-domain antibody development is prioritizing the use of VHH domains, or Nanobodies, to overcome the stability limitations inherent in traditional fragment engineering. These camelid-based binders are increasingly integrated into therapeutic platforms due to their high solubility and modularity, making them ideal components for chimeric antigen receptor (CAR) therapies that require robust antigen recognition to prevent exhaustion. The rapid commercial uptake of these specialized constructs is evident in recent industry performance; according to Johnson & Johnson's 'Fourth Quarter and Full Year 2024 Results' from January 2025, global sales of Carvykti, a CAR-T therapy incorporating a camelid-derived binding domain, surged by 92.7% to reach $963 million for the year.

Key Market Players

  • Genentech Inc.
  • AbbVie Inc.
  • Albynx, a Sanofi Company
  • Johnson and Johnson
  • Pfizer Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Novartis AG

Report Scope

In this report, the Global Antibody Fragments Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibody Fragments Market, By Product Type

  • FAB
  • scFv
  • sdAb
  • Others

Antibody Fragments Market, By Application

  • Cancer
  • Immunodeficiency
  • Others

Antibody Fragments Market, By Specificity

  • Monoclonal Antibodies
  • Polyclonal Antibodies

Antibody Fragments Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antibody Fragments Market.

Available Customizations:

Global Antibody Fragments Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antibody Fragments Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (FAB, scFv, sdAb, Others)
    • 5.2.2. By Application (Cancer, Immunodeficiency, Others)
    • 5.2.3. By Specificity (Monoclonal Antibodies, Polyclonal Antibodies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Antibody Fragments Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Specificity
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antibody Fragments Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Specificity
    • 6.3.2. Canada Antibody Fragments Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Specificity
    • 6.3.3. Mexico Antibody Fragments Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Specificity

7. Europe Antibody Fragments Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Specificity
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antibody Fragments Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Specificity
    • 7.3.2. France Antibody Fragments Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Specificity
    • 7.3.3. United Kingdom Antibody Fragments Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Specificity
    • 7.3.4. Italy Antibody Fragments Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Specificity
    • 7.3.5. Spain Antibody Fragments Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Specificity

8. Asia Pacific Antibody Fragments Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Specificity
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Antibody Fragments Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Specificity
    • 8.3.2. India Antibody Fragments Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Specificity
    • 8.3.3. Japan Antibody Fragments Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Specificity
    • 8.3.4. South Korea Antibody Fragments Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Specificity
    • 8.3.5. Australia Antibody Fragments Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Specificity

9. Middle East & Africa Antibody Fragments Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Specificity
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Antibody Fragments Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Specificity
    • 9.3.2. UAE Antibody Fragments Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Specificity
    • 9.3.3. South Africa Antibody Fragments Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Specificity

10. South America Antibody Fragments Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Specificity
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Antibody Fragments Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Specificity
    • 10.3.2. Colombia Antibody Fragments Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Specificity
    • 10.3.3. Argentina Antibody Fragments Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Specificity

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Antibody Fragments Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Genentech Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie Inc.
  • 15.3. Albynx, a Sanofi Company
  • 15.4. Johnson and Johnson
  • 15.5. Pfizer Inc.
  • 15.6. Bristol-Myers Squibb
  • 15.7. Eli Lilly and Company
  • 15.8. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer